Skip to main content

Advertisement

SpringerLink
Log in

Highlights of the annual congress of the European Association of Nuclear Medicine, Copenhagen 2007

  • Review article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Introduction

The Annual Congress of the European Association of Nuclear Medicine took place in Copenhagen on October 13–17, 2007. The event is the major scientific and professional effort in the field of nuclear medicine in Europe. The most important developments in the fields of instrumentation, radionuclide production, radiochemistry, radiotherapy, as well as the clinical imaging fields of neurology, cardiology, oncology, and general sciences were reported.

Objective

This paper emphasizes the major findings and trends at this important gathering. This review is, however, only a brief summary of the large amount of data discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14
Fig. 15
Fig. 16
Fig. 17
Fig. 18
Fig. 19
Fig. 20
Fig. 21

Similar content being viewed by others

References

  1. Perk LR, Stigter-van Walsum M, Visser GWM, Kloet RW, Vosjan MJWD, Leemans CR, et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labeled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S252.

    Google Scholar 

  2. Morgenstern A, Abbas K, Bruchertseifer F, Lebeda O, Simonelli F, Stursa J, et al. Production of U-230/Th-226 for targeted alpha therapy. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S260.

    Google Scholar 

  3. Morgenstern A, Abbas K, Bruchertseifer F, Martin S, Qu C, Simonelli F, et al. In vitro evaluation of the cytotoxicity of the novel alpha cascade emitter Th-226 in comparison with Bi-213. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S211.

    Google Scholar 

  4. Komar G, Seppänen M, Eskola O, Grönroos T, Lindholm P, Forsback S, et al. [18F]EF5: a new hypoxia-avid probe to image head and neck cancer. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S132.

    Google Scholar 

  5. Saba W, Valette H, Peyronneau M, Bramoullé Y, Coulon C, Curet O, et al. [11C]SL-25.1188, a new radioligand to study the monoamine oxidase type B with PET: preclinical characterisation. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S137.

    Google Scholar 

  6. Kao CK, Xie H, Szajek LP, Liao C, Hsu CW, Kao P. [18F]FBAU 3′,5′-dibenzoate as a potential lipophilic prodrug for neurogenesis imaging. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S138.

    Google Scholar 

  7. Serdons K, Koole M, Dupont P, Vermaelen P, Vandenberghe R, Vandenbulcke M, et al. Preclinical evaluation and human dosimetry of the new 18F-labelled amyloid imaging agent KS28. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S138.

    Google Scholar 

  8. Sharma1 SK, Joshua AV, Strelkov A, Scott JR, Abrams DN, Postema EJ, et al. Synthesis, structure activity relationship, radiolabeling and biodistribution studies on ERC-9. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S139.

    Google Scholar 

  9. Marner L, Gillings N, Gunn RN, Comley R, Baaré W, Hasselbalch SG, et al. Quantification of 11C-SB207145-PET for 5-HT4 receptors in the human brain: preliminary results. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S159.

    Google Scholar 

  10. Varrone A, Schou M, Takano A, Steiger C, Finnema S, Chalon S, et al. Preliminary evaluation of a new dopamine transporter radioligand for PET imaging: [18F]FE-PE2I. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S205.

    Google Scholar 

  11. Dong M, Lin X, Cai H, Zha J, Xue F, Zhang Z, et al. Synthesis and quality control of new molecular imaging agent (18F-FZMS) for Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S286.

    Google Scholar 

  12. Falzon CL, Ackermann U, Tochon-Danguy H, Scott A, Spratt N, Howells D, et al. Evaluation of novel PET imaging agents for the identification of the ischemic penumbra in stroke. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S332.

    Google Scholar 

  13. Haberkorn U, Mier W, Eisenhut M, Beijer B, Altmann A. Radiolabeling and biodistribution of PKF115-584, an inhibitor of the Wnt signalling pathway. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S395.

    Google Scholar 

  14. Manchanda R, Golding RGM, Zhang W, Benedum TE, Lim C, Choi SR, et al. Radiofluorinated alkynes as PET agents for the detection of amyloid plaques. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S398.

    Google Scholar 

  15. von Guggenberg E, Helbok A, Sallegger W, Andreae F, Virgolini IJ, Decristoforo C. New class of radiolabelled minigastrins for targeting CCK2 positive tumours. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S179.

    Google Scholar 

  16. Garcia Garayoa E, Schweinsberg C, Maes V, Blanc A, Bläuenstein P, Tourwé D, et al. Double targeting of prostate cancer xenografts with radiolabeled neurotensin and bombesin analogues. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S181.

    Google Scholar 

  17. Gourni E, Bouziotis P, Paravatou M, Loudos G, Sakellios N, Psimadas D, et al. Comparative in vivo evaluation of two 99mTc-labeled bombesin derivatives. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S180.

    Google Scholar 

  18. Fragogeorgi EA, Zikos C, Paravatou M, Bouziotis P, Mitsokapas N, Xanthopoulos S, et al. In vitro and in vivo evaluation of new 99mTc-bombesin analogues for diagnostic applications. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S189.

    Google Scholar 

  19. Zlatopolskiy B, Urusova E, Neumaier B, Vogg ATJ, Reske SN. Preparation and radiolabeling of DOTA-extended SOM230 analogues. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S190.

    Google Scholar 

  20. Aruva MR, Zhang K, Shanthly N, Cardi CA, Patel CA, Rattan S, et al. PET imaging of prostate cancer: a new approach to an old problem. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S190.

    Google Scholar 

  21. Pöyhönen TA, Huttunen M, Autio A, Virsu P, Salomäki S, Wilson I, et al. [68]Ga-DOTA-peptide targeting matrix metalloproteinase 9 in melanoma xenografts. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S200.

    Google Scholar 

  22. Behe M, Baumeister P, Laverman P, Boerman OC, Oyen WJG, Ramaswamy A, et al. Beta-cell imaging with radiolabelled GLP-1 analogs. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S201.

    Google Scholar 

  23. Hsia C, Lin C, Shen L, Chen H, Su Y. Preparation and biological characterization of novel HL91-derivative analog for hypoxic tumor imaging. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S202.

    Google Scholar 

  24. Miot-Noirault E, Redini F, Vidal A, Rapp M, Gouin F, Madelmont J, et al. 99mTc-NTP 15–5 imaging for the early and specific diagnosis of chondrosarcoma: proof of concept in rats. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S251.

    Google Scholar 

  25. Martini D, Valentini G, Panichelli P, Malizia C, Colonna M, Castignani L, et al. Synthesis, characterization and preliminary biological evaluation of [64Cu]ethhylenedicysteine-nitroimidazole and comparative studies with [18F]fluoromisonidazole. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S331.

    Google Scholar 

  26. Autio AK, Pöyhönen TA, Virsu P, Salomäki A, Jalkanen S, Roivainen A. Tumour versus inflammation imaging. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S397.

    Google Scholar 

  27. Blower PJ, Surfraz M, King R, Biagini S, Mather SJ. How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S148.

    Google Scholar 

  28. Surfraz M, King R, Mather S, Biagini S, Blower P. Technetium-binding in labelled HYNIC-peptide conjugates: role of coordinating amino acids. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S148.

    Google Scholar 

  29. Ahlgren S, Orlova A, Tran T, Abrahmsén L, Feldwisch J, Tolmachev V. Targeting of HER2-expressing tumours using directly 99mTc-labelled recombinant Affibody molecule ZHER2:342 with C-terminal engineered cysteine. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S190.

    Google Scholar 

  30. Vandenberghe S, Lemahieu I. Impact of time-Of-flight on reconstruction performance and image quality. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S238.

    Google Scholar 

  31. Lamare F, Bettinardi V, Visvikis D. A simplified local respiratory motion correction (LRMC) for PET/CT imaging. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S145.

    Google Scholar 

  32. Pena H, Cantinho GG, Shwartz SC, Figueiredo S, Marona D, Monteiro J, et al. Wide beam reconstruction technology—does it respect myocardial perfusion SPECT functional parameters? Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S124.

    Google Scholar 

  33. Serdons K, Koole M, Dupont P, Vermaelen P, Vandenberghe R, Vandenbulcke M, et al. Preclinical evaluation and human dosimetry of the new 18F-labelled amyloid imaging agent KS28. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S138.

    Google Scholar 

  34. Nikolaus S, Beu M, Antke C, Kley K, Wirrwar A, Müller H. In vivo quantitation of endogenous DA release in the rat striatum using small animal tomography. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S159.

    Google Scholar 

  35. Camacho V, Estorch M, Paredes P, Flotats A, Rodriguez-Revuelto A, Rivera E, et al. Usefulness of cardiac MIBG scintigraphy to differentiate Lewy Bodies Dementia from other neurodegenerative disease with cognitive impairment. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S153.

    Google Scholar 

  36. Umeda IO, Sema H, Suzuki S, Kurihara J, Kosano H, Kaminaga T, et al. 99mTc-sestamibi washout induced by the reversible hypoxic damage in electrically paced, isolated rat hearts. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S276.

    Google Scholar 

  37. Fonge H, Vunckx K, Lixin J, Wang H, Prinsen K, Lemmens C, et al. Non invasive in vivo µSPECT imaging of apoptosis and necrosis in rabbits with a novel site specific 99mTc-labelled annexin-A5-HYNIC derivative and mono-[123I]iodohypericin after acute reperfused myocardial infarction. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S149.

    Google Scholar 

  38. Prior JO, Modolo L, Kosinski M, Allenbach G, Malterre J, Valenta I, et al. Myocardial blood flow quantitation using Rubidium-82 cardiac PET: direct comparison with oxygen-15 water in volunteers and patients. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S170.

    Google Scholar 

  39. Kajander S, Ukkonen H, Knuuti J. Low dose sequential and conventional spiral cardiac CT angiography with a Hybrid CT-PET-scanner: image quality and dose comparison. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S150.

    Google Scholar 

  40. Rehak Z, Fojtik Z, Opl P, Hofirek I, Bolcak K, Niznanska V, et al. The role of 18F-FDG PET in the diagnosis of large vessel vasculitis. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S285.

    Google Scholar 

  41. Hubalewska-Dydejczyk A, Stompór T, Kalembkiewicz M, Mikolajczak R, Sowa-Staszczak A, Krzanowski M, et al. The association between carotid artery plaque scintigraphy using 131I-labelled IL-2 and serum levels of inflammatory markers in end-stage renal disease (ESRD) patients treated with peritoneal dialysis (PD). Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S233.

    Google Scholar 

  42. Laitinen I, Marjamäki P, Haaparanta M, Någren K, Laine VJO, Leppänen P, et al. Uptake of 11C-PK11195, a marker of inflammatory cells, into atherosclerotic plaques in mice. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S233.

    Google Scholar 

  43. Chua S, Groves A, Kayani I, Menezes L, Gacinovic S, Du J, et al. The impact of 18F-FDG PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S184.

    Google Scholar 

  44. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis–meta-analysis. Radiology 2005;237(1):123–31.

    Article  PubMed  Google Scholar 

  45. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224(3):748–56.

    Article  PubMed  Google Scholar 

  46. Kong G, Jackson C, Koh D, Sharma B, Lewington V, Cook G. The value of 18-FDG PET/CT in the management of colorectal liver metastases—comparison with CT and Liver MRI. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S184.

    Google Scholar 

  47. Strobel K, Schäfer M, Veit-Haibach P, Pestalozzi B, Seifert B, Clavien P, et al. Contrast enhanced FDG-PET/CT—“one stop shop” imaging for pancreatic cancer resectability assessment. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S162.

    Google Scholar 

  48. Izarduy L, Mucientes J, Lapeña L, Martínez M, Rodríguez B, Carmona E, et al. Diagnostic efficacy of PET and PET/CT in evaluation of treatment response in Hodgkin disease and non-Hodgkin lymphomas: a systematic review. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S298.

    Google Scholar 

  49. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25(5):579–86.

    Article  PubMed  Google Scholar 

  50. de Geus-Oei L, van der Heijden HFM, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, et al. Chemotherapy response evaluation with FDG-PET in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S143.

    Google Scholar 

  51. Castellucci P, Sansovini M, Farsad M, Montini G, Nanni C, Di Fabio F, et al. 18F-FDG PET/CT before and after radio-chemotherapy in patients with lower rectal cancer. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S299.

    Google Scholar 

  52. Cascini GL, Avallone A, Delrio P, Guida C, Tatangelo F, Marone P, et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 2006;47(8):1241–8.

    PubMed  CAS  Google Scholar 

  53. Huchet V, Gutman F, Kerrou K, Cussenot O, Haab F, Doublet J, et al. Evaluation of PSA velocity as a selection criterion for FCH PET/CT in patients with biological recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S123.

    Google Scholar 

  54. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34(7):982–93.

    Article  PubMed  CAS  Google Scholar 

  55. Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46(Suppl 1):172S–8S.

    PubMed  CAS  Google Scholar 

  56. Baum RP, Prasad V, Fanti S. Detection of unknown primary neuroendocrine tumors (CUP-NET) using somatostatin receptor PET/CT: results from two European Centers. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S174.

    Google Scholar 

  57. Prasad V, Secknus MA, Lauer B, Baum RP. Incidence and detection of cardiac metastases in patients with neuroendocrine tumors (NET): Role of Ga-68 DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S193.

    Google Scholar 

  58. Valdes Olmos RA, Van der Poel HG, Sivro F, Horenblas S, Hoefnagel CA, et al. SPECT-CT for anatomical sentinel node localization in prostate cancer. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S311.

    Google Scholar 

  59. Spanu A, Chessa F, Meloni GB, Sanna D, Cottu P, Manca A, et al. The role of high resolution planar scintimammography with dedicated breast camera (DBC) in the diagnosis of primary breast cancer (BC). Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S306.

    Google Scholar 

  60. Spanu A, Chessa F, Meloni GB, Sanna D, Cottu P, Manca A, et al. The usefulness of high resolution planar scintimammography with dedicated breast camera in the diagnosis of multifocal/multicentric primary breast cancer (BC). Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S306.

    Google Scholar 

  61. Dimou E, Peck-Radosavljevic M, Marosi C, Roessler K, Dietrich W, Nasel C, et al. Value of tumor imaging using (123)I-vascular endothelial growth factor-165 (123I-VEGF165). Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S215.

    Google Scholar 

  62. Cornelissen B, Oltenfreiter R, Kersemans V, Staelens L, Frankenne F, Foidart JM, et al. In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl Med Biol 2005;32(5):431–6.

    Article  PubMed  CAS  Google Scholar 

  63. Gmeiner Stopar T, Fettich J, Mlinaric-Rascan I, Hojker S, Slodnjak I, Socan A, et al. 99mTc labeled Rituximab: a new non-Hodgkin’s lymphoma imaging agent—first experience. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S307.

    Google Scholar 

  64. Baum RP, Wehrmann C, Zachert C, Mundschenk J, Prasad V, Wortmann R, et al. 5-year follow-up of peptide receptor radionuclide therapy (PRRT) in 379 patients with progressive somatostatin receptor positive neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S220.

    Google Scholar 

  65. Iten F, Müller B, Mäcke HR, Müller-Brand J, Walter MA. Survival after (90Y-DOTA)-TOC therapy in metastasized de-differentiated thyroid cancer: long-term results of a phase IIA clinical trial. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S207.

    Google Scholar 

  66. Iten F, Müller B, Schindler C, Rochlitz C, Oertli D, Mäcke HR, et al. Response to (90Y-DOTA)-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase IIA clinical trial. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S207.

    Google Scholar 

  67. Wild D, Frischknecht M, Good S, Zhang H, Morgenstern A, Bruchertseifer F, et al. Targeted radiotherapy of gastrin-releasing-peptide (GRP) receptor expressing prostate cancer: therapeutic efficacy of 213Bi vs. 177Lu labelled DOTA-PEG4-Bombesin (7–14)(DOTA-PESIN). Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S240.

    Google Scholar 

  68. Brouwers AH, Mulders PF, de Mulder PH, van den Broek WJ, Buijs WC, Mala C, et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 2005;23(27):6540–8.

    Article  PubMed  CAS  Google Scholar 

  69. Stillebroer AB, Hendrickx BW, Oosterwijk E, de Weijer K, Steffens MG, Boerman OC, et al. Radioimmunotherapy of advanced renal cell carcinoma in patients with Lutetium-177 labeled monoclonal antibody cG250. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S169.

    Google Scholar 

  70. Poepperl G, Goetz C, Rachinger F, Gildehaus FG, Schnell O, Tonn JC, et al. Intracavavitary radioimmunotherapy in malignant gliomas using 1–131 and Re-188-labelled monoclonal anti-tenascin antibodies. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S136.

    Google Scholar 

  71. Wehrmann C, Senfleben S, Baum RP. Dosimetry in peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-TATE: intra- and inter-patient variability. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S178.

    Google Scholar 

  72. Ferrari M, Cremonesi M, Bartolomei M, Orsi F, De Cicco C, Bonomo G, et al. Selective internal radiation therapy (SIRT) with 90Y-microspheres: dosimetric and radiobiological considerations for multi-cycle treatments. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S178.

    Google Scholar 

  73. Iagaru A, Zhu H, Mari C, Knox SJ, Ganjoo K, Goris ML. Comparison of 131I-Tositumomab (Bexxar®) and 90Y-Ibritumomab (Zevalin®) therapy of refractory/relapsed non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S168.

    Google Scholar 

  74. Freudenberg LS, Jentzen W, Müller SP, Bockisch A. Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I-PET. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S198.

    Google Scholar 

  75. Mihailovic J, Stefanovic L, Malesevic M. Radioiodine (131I) uptake in distant metastases as a predicting factor of survival in differentiated thyroid carcinoma patients. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S231.

    Google Scholar 

  76. Rajic MP, Ilic SS, Vlajkovic MZ, Avramovic MZ, Stevic M, Sekulic V, et al. Comparison of two methods for glomerular filtration rate measurements: modification of diet in renal disease formula and 99mTc-DTPA clearance. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S228.

    Google Scholar 

  77. Bashir H, Anderson PJ, Biassoni L, Ridout D, Gordon I. Indirect radionuclide cystography in children—a review of practice and experience. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S250.

    Google Scholar 

  78. Nichols KJ, Tomas MB, Tronco GG, Palestro CJ. Factors affecting sensitivity for detection of parathyroid lesions. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S197.

    Google Scholar 

  79. Basu S, Dadparvar S, Housenic M, Chryssikos T, Bural G, Alzeair S, et al. The value of FDG-PET for the evaluation of painful hip and knee arthroplasties: comparison with 111In-labeled leukocyte/99mTc-sulfur colloid marrow imaging. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S155.

    Google Scholar 

Download references

Acknowledgment

We thank Kjell Nagren, MSc, for studying and collecting the new radioligands at the EANM Congress. We also thank Ms. Mirja Jyrkinen for the technical assistance with the article.

Author information

Authors and Affiliations

  1. Turku PET Centre, Turku University Central Hospital, P.O. Box 52, 20521, Turku, Finland

    Juhani Knuuti

  2. Division of Nuclear Medicine, University Hospital of Liège, Liege, Belgium

    Roland Hustinx

Authors
  1. Juhani Knuuti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roland Hustinx
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juhani Knuuti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knuuti, J., Hustinx, R. Highlights of the annual congress of the European Association of Nuclear Medicine, Copenhagen 2007. Eur J Nucl Med Mol Imaging 35, 655–672 (2008). https://doi.org/10.1007/s00259-007-0674-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0674-0

Keywords

Search

Navigation